dextropropoxyphene
Trade name: Darvon
Approved
Nov 12, 1957
Dextropropoxyphene is an analgesic in the opioid category, patented in 1955 and manufactured by Eli Lilly and Company. It is an optical isomer of levopropoxyphene. It is intended to treat mild pain and also has antitussive and local anaesthetic effects. The drug has been taken off the market in Europe and the US due to concerns of fatal overdoses and heart arrhythmias. It is still available in Australia, albeit with restrictions after an application by its manufacturer to review its proposed banning. Its onset of analgesia is said to be 20–30 minutes and peak effects are seen about 1.5–2.0 hours after oral administration. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 1 marketing orgs
Earliest trial started Jan 1, 2004 (NCT00378937)
Timeline
1950s
- Nov 12, 1957
Earliest FDA Approval
Indications
Approved for
Studied for
Mechanism of action
Cannabinoid receptor 1/Mu-type opioid receptor agonist
Approval history
- approvedNov 12, 1957
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDextropropoxyphene ↗
Also known as
- destropropossifene
- destropropossifene
- destropropoxifene
- dextropropoxifeno
- dextropropoxifeno
- dextropropoxiphene chloride
- dextropropoxyphen
- dextropropoxyphen
- dextropropoxyphen
- dextropropoxyphene
- dextropropoxyphene
- dextropropoxyphene
- dextropropoxyphene
- dextropropoxyphene
- dextropropoxyphene
- dextropropoxyphene
- dextropropoxyphene
- dextropropoxyphène
- dextropropoxyphène
- dextro propoxyphene hcl
- dextropropoxyphene hydrochloride
- dextropropoxyphene hydrochloride
- dextropropoxyphene napsilate
- dextropropoxyphene napsilate
- dextropropoxyphene napsylate
- dextropropoxyphenum
- dextropropoxyphenum
- d-propoxyphene
- d-propoxyphene
- d-propoxyphene
- d-propoxyphene napsylate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00378937 | Phase 4 | Jan 1, 2004 | University of Bristol |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Bristol | Academic/Hospital | 1 | 1 | 1 | 2004 |
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Eli Lilly | For profit | NDA | — |